Clinical Pathways Congress
September 16-18 marked the inaugural Clinical Pathways Congress, the official meeting of Journal of Clinical Pathways (JCP), which served as the first forum of its kind to help stakeholders work together to develop strategies to ensure that pathways are designed to align with the needs of patients, providers, and payers. For these three days, some of the leading experts in clinical pathway development, precision medicine, oncology management, and patient advocacy gathered in Boston, MA, to discuss these and other important issues related to the implementation of clinical pathways in oncology.
The Steering Committee included leading pathway experts JCP Editor-in-Chief Winston Wong, PharmD, W-Square Group; Aymen Elfiky, MD, MPH, MSc, Dana Farber Cancer Institute, Brigham and Women’s Hospital, and JCP Editorial Advisory Board member; Bruce Feinberg, DO, Cardinal Health Specialty Solutions, and JCP Editorial Advisory Board member; Dwight E Heron, MD, MBA, FACRO, FACR, UPMC Cancer Center, and JCP Editorial Advisory Board member; Michael Kolodziej, MD, Flatiron Health; and Robin T Zon, MD, FACP, FASCO, Michiana Hematology Oncology and Chair of the American Society of Clinical Oncology (ASCO) Clinical Pathways Task Force.
The inaugural meeting featured speakers offering a wide range of perspectives on clinical pathways in oncology. Below are some highlights of the meeting.
Richard Schilsky, MD, senior vice president and chief medical officer of the American Society of Clinical Oncology kicked off the meeting with his Keynote Address on the relationship between clinical pathways development and the emergence of precision medicine.
In a presentation at the inaugural Clinical Pathways Congress, Dr Kolodziej argued that clinical pathways as we know them will cease to exist as a result of the rise of immunotherapies for the treatment of cancer.
Dr Zon, first author of the recently released ASCO Policy Statement on Clinical Pathways in Oncology, was joined by Andrew Hertler, MD, FACP, New Century Health, and Dr Kolodziej to discuss the Policy Statement and its implications.
In an early session at the Clinical Pathways Congress, Bert H O’Neil, MD, Indiana University Simon Cancer Center, discussed some of the important factors to consider when developing a clinical pathway for colorectal cancer.
“It is time to rethink how we treat chronic lymphocytic leukemia (CLL),” said Chadi Nabhan, MD, MBA, FACP, Cardinal Health Specialty Solutions, who spoke at length about the shifting landscape of oncology care and the role of clinical pathways.
A discussion about clinical pathways for non-small cell lung cancer was led by David Jackman, MD, who designed the pathways program for NSCLC at Dana Farber Cancer Instutute.
With his presentation, Alan Balch, PhD, Patient Advocate Foundation, brought to the discussion the much needed perspective of the patient.